Publications
207
Citations
4,728
Est. group size
~13
Recurring co-author estimate
Active years
25
Publishing since 2002
Amanda B. Hummon's research uses mass spectrometry-based techniques, including imaging and proteomics, to study cancer biology, with a particular focus on colorectal and ovarian cancers and 3D tumor spheroid models. Her work combines analytical chemistry methods with cancer genomics to understand tumor drug response, protein modifications, and gene expression changes linked to chromosomal abnormalities (aneuploidy). This research bridges chemistry and cancer biology to develop tools for studying how drugs distribute and act within tumor tissue.
Publication output was relatively steady at 6-12 per year from 2017-2022, followed by a large spike in 2023 (68 items, likely including many supplementary data files) before returning to a steadier 7-8 per year in 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Matrix-assisted laser desorption/ionization imaging mass spectrometry
Nature Reviews Methods Primers · 2026
- Discovery and targeted mass spectrometry-based proteomics of ovarian cancer
Expert Review of Proteomics · 2025
- Quantitative mass spectrometry imaging: therapeutics & biomolecules
Chemical Communications · 2024
- Development of Spheroid-FPOP: An In-Cell Protein Footprinting Method for 3D Tumor Spheroids
Journal of the American Society for Mass Spectrometry · 2023
- Quantification of Irinotecan in Single Spheroids Using Internal Standards by MALDI Mass Spectrometry Imaging
Analytical Chemistry · 2023
- Evaluating the Pharmacokinetics and Pharmacodynamics of Chemotherapeutics within a Spatial SILAC-Labeled Spheroid Model System
Analytical Chemistry · 2023
- Data from Gene Expression Profiling Reveals a Massive, Aneuploidy-Dependent Transcriptional Deregulation and Distinct Differences between Lymph Node–Negative and Lymph Node–Positive Colon Carcinomas
2023
- Supplementary Tables 1-5 from Gene Expression Profiling Reveals a Massive, Aneuploidy-Dependent Transcriptional Deregulation and Distinct Differences between Lymph Node–Negative and Lymph Node–Positive Colon Carcinomas
2023
- Supplementary Figure 1 from Gene Expression Profiling Reveals a Massive, Aneuploidy-Dependent Transcriptional Deregulation and Distinct Differences between Lymph Node–Negative and Lymph Node–Positive Colon Carcinomas
2023
- Data from Genetic Amplification of the NOTCH Modulator LNX2 Upregulates the WNT/β-Catenin Pathway in Colorectal Cancer
2023
- Data from Gene Expression Profiling Reveals a Massive, Aneuploidy-Dependent Transcriptional Deregulation and Distinct Differences between Lymph Node–Negative and Lymph Node–Positive Colon Carcinomas
2023
- Supplementary Figure 1 from Gene Expression Profiling Reveals a Massive, Aneuploidy-Dependent Transcriptional Deregulation and Distinct Differences between Lymph Node–Negative and Lymph Node–Positive Colon Carcinomas
2023
- Supplementary Tables 1-5 from Gene Expression Profiling Reveals a Massive, Aneuploidy-Dependent Transcriptional Deregulation and Distinct Differences between Lymph Node–Negative and Lymph Node–Positive Colon Carcinomas
2023
- Supplementary Figure S7 from Genetic Amplification of the NOTCH Modulator LNX2 Upregulates the WNT/β-Catenin Pathway in Colorectal Cancer
2023
- Supplementary Figure S1 from Genetic Amplification of the NOTCH Modulator LNX2 Upregulates the WNT/β-Catenin Pathway in Colorectal Cancer
2023
- Analytical Chemistry×15
- Journal of Proteome Research×9
- Journal of the American Society for Mass Spectrometry×8
- Analytical and Bioanalytical Chemistry×5
- PROTEOMICS×4
- Randall K. Julian
Chemistry · Purdue University West Lafayette
- Emily R. Sekera
Chemistry · The Ohio State University
- Arbil Lopez
Chemistry · The Ohio State University
- Yi Du
Chemistry · Purdue University West Lafayette
- James P. Reilly
Chemistry · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile